This study is testing an investigational drug called WAL0921 for people with certain kidney diseases, including diabetic nephropathy, primary focal segmental glomerulosclerosis (FSGS), minimal change disease, primary IgA nephropathy, and primary membranous nephropathy. You might be able to join if you are an adult between 18 and 75 years old and have one of these conditions with an eGFR (a measure of kidney function) of 30 mL/min or higher. Participants will receive either WAL0921 or a placebo (an inactive substance) through an IV every two weeks for a total of seven infusions. The main goal is to see how safe WAL0921 is by tracking any side effects up to 36 weeks.

Study design

This is a randomized, double-blind study, meaning participants are randomly assigned to receive either WAL0921 or a placebo, and neither you nor your doctors will know which you are receiving. The study plans to enroll 96 participants.

What's involved

You would receive an intravenous infusion of either WAL0921 or placebo once every two weeks for a total of seven infusions. You will then be followed for 24 weeks after your last infusion.

Compensation

Not stated in the trial record.

Follow-up

All subjects will be followed for 24 weeks after their last infusion.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.